BRCA2 and breast carcinoma: In vitro experiments performed in two breast cancer cell lines, one showing a BRCAness phenotype due to a BRCA2 mutation, show an increased synergy between olaparib and everolimus in the BRCA2 mutated cell line as compared to the BRCA wild-type (Figure 6).